A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

Phase 2

Completed

• Conditions: Lymphangioleiomyomatosis
• Interventions: Drug: Everolimus

• Registration Number: NCT01059318
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

This was an exploratory study to determine whether escalating doses of RAD001 (everolimus) were safe and effective in patients with Lymphangioleiomyomatosis

Detailed Description

In addition to the data collected in this study, historical data from 43 patients treated with placebo from the multicenter trial of sirolimus in LAM (MILES) study (NCT00414648) were down weighted to an effective sample size of 18 for comparison of FEV1 and FVC endpoints. Reference to the publication of the MILES study has been provided under "Result Publication".

Study Timeline

• Study Start: 2010-01
• Study First Submitted: 2010-01-28
• Study First Submitted QC: 2010-01-28
• Study First Posted: 2010-01-29
• Primary Completion: 2012-06
• Study Completion: 2012-06
• Results First Submitted: 2013-06-14
• Status Verified: 2020-10
• Results First Submitted QC: 2020-11-16
• Last Update Submitted: 2020-11-16
• Results First Posted: 2020-11-19
• Last Update Posted: 2020-11-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 24

Inclusion Criteria

• Female aged >/= 18 years with a diagnosis of LAM
• Pulmonary function abnormalities as follows:
• FEV1 of ≤ 80% of the predicted value following administration of a standard dose of a short acting β2-agonist (*200 µg Salbutamol, measured between 10 and 15 minutes of inhalation) OR
• FEV1 < 90% of the predicted value of bronchodilator following administration of a standard dose of a short acting β2-agonist (*200 µg Salbutamol, measured between 10 and 15 minutes of inhalation) and DLco (uncorrected) <80% predicted.
• Female patients including those of childbearing potential will be included in this study.
• Negative pregnancy test at screening and baseline

Exclusion Criteria

• FEV1<50% of predicted post-bronchodilator.
• Change in FVC (ml) > ± 15% of screening value at baseline visit (not less than 14d after screening visit).
• Use of any medicine containing estrogen in the 4 months prior to the screening visit and for the duration of the study
• Significant hematologic, renal, hepatic laboratory abnormality or amylase > 1.5x the upper limit of the normal range at the screening or baseline visits
• Fasting blood glucose > 126mg/dl or random blood glucose >200mg/dl at screening and/or baseline
• Recent surgery (involving entry into a body cavity or requiring sutures) within 2 months of the screening visit or any evidence of unhealed surgical wound.
• Uncontrolled hyperlipidemia (defined as persistent elevation of total cholesterol or triglycerides >6.5nM/L) or a history of clinical atherosclerotic disease including heart attack, angina, peripheral vascular disease or stroke.
• Previous organ transplantation
• Inability to give informed consent
• Inability to perform pulmonary function or 6 minute walk tests and imaging assessments

Other protocol-defined inclusion/exclusion criteria may apply

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Everolimus	Everolimus	All patients received a starting dose of everolimus 2.5mg/day for 4 weeks, followed by a dose of 5 mg/day for 4 weeks and finally a dose of 10mg/day for 18 weeks. The 26 week treatment period was followed by an optional extension period wherein patients continued therapy until the last patient had completed 26-weeks of treatment. The longest period a patient participated in the study was 62 weeks.

Primary Outcome Measures

Name	Time	Method
Change From Baseline in Vascular Endothelial Growth Factor-D (VEGF-D) Concentrations	Baseline, 26 weeks	Blood samples (1 mL) for determination of VEGF-D were collected from a forearm vein (direct venipuncture or from an indwelling cannula) and 2 aliquots of serum were collected. VEGF-D levels were determined from only 1 of the 2 serum aliquots, with the second acting as a back-up. A serum VEGF-D \>800 pg/mL level supports a diagnosis of Lymphangioleiomyomatosis (LAM)
Mean Trough (C0,ss) and Peak (C2,ss) Drug Concentration at Steady State	pre-dose and at 2 hour post dose at week 26	Venous blood samples (2 mL) for pharmacokinetic evaluation were collected pre dose and 2 hours post dose at preselected visits.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in 6-minute Walk Test Score to Measure Exercise Capacity	Baseline, 26 weeks	A standardized 6-minute walk test (6MWT) was performed in accordance with the guidelines of the American Thoracic Society 2002. The test was done about the same time of day to avoid diurnal variation in an environment that had an adequate temperature to avoid additional burden to the patient due to heat or cold air. The distance walked in six minutes (6MWD) was recorded.
Change From Baseline in Forced Vital Capacity (FVC)	Baseline, 26 weeks	All spirometry evaluation followed recommendations of the Standardization of Lung Function Testing. All spirometry maneuvers were performed in sitting position whilst wearing nose clips. At least three acceptable maneuvers were performed for each time point, and results met within-test and between-test criteria for acceptability. The highest value was obtained of FVC from any of the three maneuvers that met acceptability criteria. Change from baseline in FVC was compared between everolimus and historical placebo data from multicenter trial of sirolimus in LAM. (MILES NCT00414648) due to absence of placebo group in this current study on a rare lung disease. These two studies had different study designs, so the change from baseline to 6 months (26 weeks) in MILES study was estimated from the publicly reported rate of change per month to provide a meaningful comparison. This historical control be can be viewed on the Novartis Clinical Trial Results website.
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)	Baseline, 26 weeks	All spirometry evaluation followed the recommendations of the Standardization of Lung Function Testing. All spirometry maneuvers were performed in the sitting position whilst wearing nose clips. At least three acceptable maneuvers were performed for each time point, and the results met within-test and between-test criteria for acceptability. The highest value was obtained of FEV1 from any of the three maneuvers that met acceptability criteria.; Change from baseline in FEV1 was compared between everolimus and historical placebo data from the MILES study (NCT00414648) due to the absence of a placebo group in this current study on a rare lung disease. These two studies had different study designs, so the change from baseline to 6 months (26 weeks) in MILES study was estimated from the publicly reported rate of change per month in order to provide a meaningful comparison. This historical control can be viewed on the Novartis Clinical Trial Results website.
Change From Baseline in Extended Pulmonary Function Testing	Baseline, 26 weeks	Extended pulmonary function testing such as Total Lung Capacity (TLC), Thoracic Gas Volume (TGV), Residual Volume (RV) were measured using a body plethysmograph
Change From Baseline in Carbon Monoxide Diffusing Capacity (DLCO)	Baseline, 26 weeks	Carbon Monoxide Diffusing Capacity (DLCO) one of the extended pulmonary function testing which was also measured using a body plethysmograph.
Change From Baseline in Oxygen Saturation	Baseline, 26 weeks	Oxygen saturation means the amount of oxygen in blood stream. Oxygen saturation was measured by using a Pulse Oximeter.

Trial Locations

Locations (3)

Center for LAM Research and Clinical Care; 🇺🇸 Boston, Massachusetts, United States

Novartis Investigative Site; 🇮🇹 Milan, Italy

University of Cincinnati, Department of Internal Medicine, Pulmonary, Critical Care & Sleep Medicine,; 🇺🇸 Cincinnati, Ohio, United States